Frequently Asked Questions
The market is segmented based on Global Immuno-Oncology (IO) Market, By Type (Immune Cell Therapy (CAR-T), Monoclonal Antibodies, Checkpoint Inhibitors, Cytokines, Cancer Vaccines, Others), Targets (IDO1i, oncolytic virus, STING agonist, TLR agonist, TIL, MEKi, TIGIT, CPI, GITR agonist, TGF-b trap, A2AR antagonist/CD73i, LAG-3, anti-CTLA-4, MAGE-A3, VEGF, HDAC, STING, TIM-3, TGF-Beta, OX40, Others), Indication (Malignant Tumors, Benign Tumors, Others), End Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) – Industry Trends and Forecast to 2030.
.
The Global Immuno Oncology Market size was valued at USD 28.10 USD Billion in 2022.
The Global Immuno Oncology Market is projected to grow at a CAGR of 23.9% during the forecast period of 2023 to 2030.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
